Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

16. november 2026 oppdatert av: University of Zurich

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.

Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.

A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.

Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

54

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Canton of Zurich
      • Zurich, Canton of Zurich, Sveits, 8091
        • University Hospital Zurich
        • Ta kontakt med:
          • Matthias Guckenberger
        • Ta kontakt med:
          • Tiuri Kroese
    • Baden-Würtemberg
      • Heidelberg, Baden-Würtemberg, Tyskland, 69120
        • University Clinic Heidelberg
        • Ta kontakt med:
          • Jürgen Debus

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion criteria include:

  • Regionally metastatic prostate cancer (cN1, cT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
  • Good to moderate performance status (WHO 0-2)
  • Written informed consent.
  • A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.
  • Age ≥ 18 years

Exclusion criteria include:

  • >5 regional lymph nodes

  • Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)

  • Previous radiotherapy to the pelvis or prostate

  • Previous radical prostatectomy

  • Large body size that would not fit into the MRI-simulator bore

  • Presence of distant metastases (i.e. cM1)

    • Non-regional lymph nodes (M1a):
    • Bone metastases (M1b)
    • Other sites (M1c)
  • Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).

  • Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).

  • Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).

  • Inability to follow procedures or insufficient knowledge of project language, inability to give consent.

  • Participation in a clinical trial which might influence the results of this project.

  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

  • Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.6.0).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Single Group Study

Assessment of weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Feasibility- a successful delivery of CT or MR-informed SBRT per fraction
Tidsramme: from Day 1 of treatment up to 7 weeks until end of treatment

Feasibility will be assessed by recording whether each fraction of stereotactic body radiation therapy (SBRT), guided by computed tomography (CT) or magnetic resonance (MR) imaging, is successfully delivered according to the planned treatment parameters. Successful delivery is defined as completion of the planned fraction without protocol deviations or technical interruptions. Data will be summarized as the proportion of fractions successfully delivered per patient and overall. Every treatment fraction having passed the point of entry into the adaptive workflow will be analyzed for this endpoint.

from Day 1 of treatment up to 7 weeks until end of treatment
Safety - Adverse events
Tidsramme: ≥ 3 months to within 1 year after completion of SBRT

The presence of genitourinary or gastrointestinal toxicity of grade ≥ 3 within 1 year after completion of radiotherapy (according to CTCAE v5.0). Treatment-related discontinuation. and Subgroup analyses will be performed for patients with and without regional lymph node metastases (i.e., cN0 versus cN1).

≥ 3 months to within 1 year after completion of SBRT

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Biochemical progression-free survival
Tidsramme: from Day 1 up to 5 years after treatment

This will be determined from the start of therapy until the occurrence of PSA recurrence according to the Phoenix criteria i.e. post- therapeutic PSA nadir + 2 ng/ml

from Day 1 up to 5 years after treatment
Castration-resistant free survival
Tidsramme: from Day 1 up to 5 years after treatment

Castration-resistant free survival defined as cancer progression despite low (castrate) levels of testosterone (<50 ng/dL). Cancer progression is defined as:

  • Biochemical progression: ≥2 consecutive PSA rises (at least 1 week apart)
  • Radiologic progression: appearance of new lesions on imaging
from Day 1 up to 5 years after treatment
Patients Quality of Life EQ-5D-5L from the European Organisation for Research and Treatment of Cancer
Tidsramme: from Day 1 up to end of study until 5 years

Quality-of-life will be measured using the EQ-5D-5L questionnaire during and after treatment

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

from Day 1 up to end of study until 5 years
Patients Quality of Life QLQ-C30 from the European Organisation for Research and Treatment of Cancer
Tidsramme: From Day 1 up to end of study (up to 5 years)

Quality of life will be measured using the EORTC QLQ-C30 questionnaire. This instrument includes functional scales, symptom scales, and a global health status/quality-of-life scale. All scores are linearly transformed to a 1-4 scale. For functional scales and global health status, higher scores indicate better functioning or quality of life, whereas for symptom scales/items, higher scores indicate greater symptom burden.

From Day 1 up to end of study (up to 5 years)
Adverse events
Tidsramme: from Day 1 until 5 years or end of Study

Genitourinary and Gastrointestinal toxicity measured with Common Terminology Criteria for Adverse Events (CTCAE)

from Day 1 until 5 years or end of Study
Patients overall survival
Tidsramme: from Day 1 until Progression or death whichever comes first until 5 years

defined from the start of therapy until death or censoring

from Day 1 until Progression or death whichever comes first until 5 years
Patient overall treatment - Patient treatment workflow duration (time from MRI scan start to completion of treatment)
Tidsramme: from Day 1 start of therapy, weekly until end of treatment up to 7 weeks

Patient will be asked from the start and end of MRI scan to start and end of treatment respectively, and for all steps from simulation to treatment delivery individually

from Day 1 start of therapy, weekly until end of treatment up to 7 weeks
Other Toxicities
Tidsramme: Day 1 of Treatment for up to 5 years or until death whichever comes first

Treatment-related toxicities other than the primary toxicity outcomes will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Other Toxicities will be evaluated during SBRT treatment and throughout follow-up for up to 5 years after completion of treatment or until patient death, whichever occurs first. The type, frequency, and severity (grade) of adverse events will be recorded according to CTCAE v5.0 criteria.

Day 1 of Treatment for up to 5 years or until death whichever comes first
Dosimetry difference
Tidsramme: from Day 1 of treatment start until end of treatment up to 7 Weeks

Dosimetry difference of the online adaptive plan compared to the original plan recalculated on the imaging of the day. Dosimetry difference is defined as difference in coverage of the planning target volume (PTV) or of one of the organs at risk e.g. bowel or rectum

from Day 1 of treatment start until end of treatment up to 7 Weeks
Anatomy changes assessed on magnetic resonance imaging (MRI)
Tidsramme: from Day 1 of treatment up to 7 weeks

Anatomical changes will be evaluated using serial magnetic resonance imaging (MRI) acquired during treatment and follow-up. Changes in relevant anatomical structures (e.g., target volume and surrounding organs at risk) will be assessed by comparing images obtained at baseline and subsequent imaging time points. Observed anatomical variations will be documented and summarized descriptively.

from Day 1 of treatment up to 7 weeks
Comparison of Patient treated and not treated
Tidsramme: from Day 1 until 5 Years of study or death

Comparison of number of patients not treated at all/not treated with all planned fractions in the CT or MR-informed workflow compared to those intended to be treated and categorization of patterns of failure within the CT or MR-informed workflow.

from Day 1 until 5 Years of study or death
Patient compliance
Tidsramme: from Day 1 until 5 Years / end of Study

Patient compliance will be measured by tracking a scheduled treatment sessions and adherence to the prescribed treatment protocol, including completion of all required procedures and instructions. Data will be collected throughout the treatment period and summarized as the proportion of scheduled sessions attended and procedures completed, as well as reasons for any missed sessions or deviations from the protocol.

from Day 1 until 5 Years / end of Study
Patient well being and comfort
Tidsramme: from Day 1 of treatment to weekly up to 7 weeks

Patients will be asked to report their comfort during and after simulation assess with a 0 to 10 numerical rating scales, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day 1 of treatment to weekly up to 7 weeks
Physician decision certainty
Tidsramme: from Day1 of treatment to weekly up to 7 weeks

clinicians will be asked to report their clinical confidence with a 0 to 10 NRS, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day1 of treatment to weekly up to 7 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Matthias Guckenberger, University of Zurich
  • Studiestol: Matthias Guckenberger, Universitätsspital Zürich
  • Hovedetterforsker: Tiuri Kroese, University of Zurich

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. juli 2029

Studiet fullført (Antatt)

1. januar 2033

Datoer for studieregistrering

Først innsendt

11. mars 2026

Først innsendt som oppfylte QC-kriteriene

12. mai 2026

Først lagt ut (Faktiske)

15. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere